future profitability, page-8

Dear makattack and burt (and others if interested)....

(sorry for delayed reply...I was distracted with my rose glasses again :-)

re IMMUNAID and in an effort to clarify...

Firstly, the rnd 1 raise recently was for 10% of the company (1m shares @ $1).

Second the funds were raised by immunaid to further its rapid expansion and pay back some debts to gtg (that as I understand funded patent costs etc over the years)

Gtg did not forgo 30% for 1m nor were they prepared to invest the same amount to expand this project...they only received what immunaid owed them for past loans etc...

this is eesentially because gtg's main focus is on brevagen and no effort or cash was being spent on immunaid as a result, despite the growing interest and the incredible (understatement) results from past/recent/current human trials.

As to the dilution issue, this is rather simple...

Essentially, gtg owned 70% of a company that (aside from its potential) was currently valued at zero. As a result of reducing their holding to 46% and the recent raise, immunaid is now valued at 10m.......so compared to 70% of nothing, they now own 46% of the company and their holding is worth 4.6m

A second round of funding will be at even higher levels (say $10) and gtg's stake may well be further reduced/diluted again.....but to follow the logic.....gtg may then only hold 35%...but this 35% will be worth say 35m
And so on etc etc.

As previously stated, the reduction in gtg's holding/stake in immunaid will allow more funding, more investors to get onboard and the ability to for Immunaids management to focus on new opportunities without delay, which are now well underway.

I understand one the most reputable and highly regarded cancer professors in Australia (Adelaide uni) recently stated that immunaid is 'the largest paradigm shift in cancer treatment etc in the last 50 years' !!

This is probably also justified by the amazing results seen so far with the trials underway. Generally, candidates for new trials are provided when nothing else has worked and sadly no further options are available, with little chance of surviving even in the short term.

Incredibly, these patients were then treated under the immunaid concept of 'timed therapy and treatments' and to everyone's surprise, not only have they survived far longer than expected by medical staff under normal treatment, but many have shown vast improvements in reducing the cancer and incredibly, some show absolutely no signs of the desease at all.

In any case, I suspect we will all be hearing far more on this subject shortly as new trials are implemented ASAP and further opportunities become apparent. (it is also suggested that the immunaid concept also applies to many other immune system related deceases such as AIDS) so stay tuned on this.

Hope this info is of some assistance.

Another positive day on NASDAQ coming our way.

GL fellow geneies !!